# Open Drug Discovery Center for Alzheimer's Disease

> **NIH NIH U54** · EMORY UNIVERSITY · 2023 · $1,142,384

## Abstract

The Open Drug Discovery Center for AD (Open-AD) Administrative and Data Management Core (Admin and
Data Core) serves three functions: (1) to provide overall administrative organization, oversight and management
for all work performed within the Open-AD, (2) to manage communications with external AD investigators across
the community including for target prioritization, and (3) to support the open distribution of all Open-AD generated
reagents, tools, probes, data, and knowledge for use by independent investigators. The Admin and Data Core
will establish and implement administrative and management structures to ensure that the Center is appropriately
meeting milestones and deliverables, is soliciting input and openly sharing assets across the community, and is
working across Cores for effective evaluation and management of target programs as they move through the
Center pipeline. In addition, the Admin Core will manage Open-AD interactions with the external research
community so as to solicit and evaluate a community-prioritized set of targets across a diverse portfolio of
therapeutic hypotheses, to identify domain experts that can serve as advisors and partners to guide decisions
around each therapeutic hypothesis that is selected, and to identify researchers that will use the assets
developed by the Center to test these (and other) therapeutic hypotheses. Interactions with the external research
community will be performed through the Open-AD AD expert panel, the External Advisory Board, an annual
Open-AD meeting, target-specific workshops, and through the Agora platform (formerly called the AMP-AD Wall
of Targets, agora.ampadportal.org). In order to invite the entire AD research community to participate in our
investigation of novel targets, the proposed Open-AD Center will adopt a radically open approach to target
validation and drug discovery. All Open-AD investigators have agreed to place all data, knowledge, reagents,
and tools including chemical and biological probes into the open domain with no intellectual property claims. To
support wide distribution and encourage reuse, Open-AD will donate the rights to distribute any reagent to
commercial suppliers, non-exclusively and for no compensation. All Center activities will be performed in the
open using the Open-AD collaboration workspace. All resources, data, and knowledge developed for each
therapeutic approach will be disseminated using standard resource (AddGene for cDNA clones, Thermo Fisher
for antibodies, etc) – and all information will be summarized and registered through the Agora platform.

## Key facts

- **NIH application ID:** 10692630
- **Project number:** 5U54AG065187-05
- **Recipient organization:** EMORY UNIVERSITY
- **Principal Investigator:** ALLAN I LEVEY
- **Activity code:** U54 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2023
- **Award amount:** $1,142,384
- **Award type:** 5
- **Project period:** 2019-09-30 → 2024-08-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10692630

## Citation

> US National Institutes of Health, RePORTER application 10692630, Open Drug Discovery Center for Alzheimer's Disease (5U54AG065187-05). Retrieved via AI Analytics 2026-05-21 from https://api.ai-analytics.org/grant/nih/10692630. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*